Leerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Stifel Downgrades Rapt Therapeutics (RAPT) to HoldNovember 12, 2024 4:04 PM Form SC 13G/A RAPT Therapeutics, Inc. Filed by: FMR LLCNovember 12, 2024 10:35 AM Form 10-Q RAPT Therapeutics, Inc. For: Sep 30November 12, 2024 9:48 AM Form 8-K RAPT Therapeutics, Inc. For: Nov 12November 12, 2024 9:27 AM RAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 8:00 AM Rapt Therapeutics (RAPT) PT Lowered to $4 at Wells FargoNovember 12, 2024 6:53 AM U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%November 11, 2024 4:54 PM Piper Sandler Downgrades Rapt Therapeutics (RAPT) to NeutralNovember 11, 2024 3:10 PM JPMorgan Downgrades Rapt Therapeutics (RAPT) to UnderweightNovember 11, 2024 11:45 AM RAPT Therapeutics (RAPT): Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryNovember 11, 2024 8:04 AM